血清MFGE8与CA125、CEA对乳腺癌诊断价值探讨

Diagnostic Value of Serum MFGE8,CA125 and CEA on Breast Cancer

目的:探讨血清中MFGE8水平及与乳腺癌诊断的关系。方法:收集62例乳腺癌患者(乳腺癌组)、49例乳腺良性肿瘤患者(良性组)及105例女性健康体检者(对照组)血清,用ELISA方法检测MFGE8水平,采用电化学发光法检测CA125和CEA水平,并对结果进行统计学分析。结果:乳腺癌组患者血清中MFGE8、CA125和CEA水平分别为(6638.5±3529.3)pg/ml、(34.58±31.26)U/ml和(4.39±3.25)ng/ml,MFGE8显著高于其他两组;乳腺癌组MFGE8、CA125和CEA的阳性率分别是65.4%、50.9%和30.3%,联合检测MFGE8、CA125和CEA,检出率可提高至85.3%。结论:血清MFGE8水平可以和CA125、CEA一同作为诊断乳腺癌的指标。

Objective：To discuss the serum level of MFGE8 and the relationship between MFGE8 and diagnosis of breast cancer.Methods：Eenzyme-linked immunosorbent assay was introduced to detect serum level of MFGE8 and electrochemiluminescence immunoassay introduced to detect serum level of CA125 and CEA.Results：The serum levels of MFGE8,CA125 and CEA in patients with breast cancer were （6638.5±3529.3）pg/ml,（34.58±31.26）U/ml and （4.39±3.25）ng/ml respectively,which were significantly higher than others.The positive incidence of MFGE8,CA125 and CEA in patients with breast cancer were 65.4%,50.9% and 30.3%.By combined detection of MFGE8,CA125 and CEA,the positive rate of breast cancer could be greatly improved to 85.3%.Conclusion：The serum level of MFGE8 can be reviewed as a kind of valuable biomarker in the diagnosis of breast cancer,together with CA125 and CEA.